医用大麻在患有肌缩性侧面硬化症的患者中的临床有效性
John Michael Austin1, Ryan Bailey1, Sandra Garcia Velazquez2
1MS4 at the University of Texas Health Science Center San Antonio (UTHSCSA), Department of Neurology, Long School of Medicine, 7703 Floyd Curl Dr, San Antonio, TX 78229, United States of America.
Journal of the neurological sciences
|September 22, 2024
概括
医用大麻 (MM) 可能缓解疼痛,食欲问题,和焦虑在肌缩侧面硬化症 (ALS) 患者短期. 然而,MM使用与更快的ALS进展有关,需要进一步研究.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 医用大麻 (MM) 的使用正在增加,用于经合法化后的肌缩侧面硬化症 (ALS) 症状管理.
- 关于MM对ALS进展和症状负担的疗效和影响的数据有限.
研究的目的:
- 追溯评估MM对ALS症状,疾病进展和患者结局的影响.
- 分析MM使用与症状流行率,BMI和ALSFRS-R下降之间的相关性.
主要方法:
- 在两年内对344名ALS患者进行了回顾性队列研究.
- 对照组 (有症状,没有MM) 和试验组 (MM处方) 的比较.
- 分析疼痛,食欲,焦虑,,失眠,ALSFRS-R和BMI使用描述性统计和局部回归.
主要成果:
- 毫米米的使用与短期缓解疼痛,食欲低下和焦虑相关.
- 在MM使用和性,失眠或BMI维持之间没有发现相关性.
- 毫米使用与更快的ALS进展 (ALSFRS-R下降) 相相关,尽管MM使用者具有更高的基线症状负担.
结论:
- MM可能为特定的ALS症状提供短期的好处,如疼痛,食欲和焦虑.
- 根据ALSFRS-R得分,MM使用与加速ALS进展有关.
- 建议进行多中心随机对照试验,以确认MM在ALS治疗中的有效性和安全性.
更多相关视频
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
Myasthenia Gravis: Diagnostic Tests
695
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
695
Direct-Acting Cholinergic Agonists: Therapeutic Uses
702
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
702
Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495


